When 'Make in India' meets global ambition!
Budget 2026: India's Bold Vision for Pharmaceutical & Healthcare Leadership India's Budget 2026 charts an ambitious roadmap to transform the nation into a global pharmaceutical and healthcare powerhouse, and the implications for our industry are profound. At the heart of this transformation is the Biopharma Shakti Initiative , a ₹10,000 crore investment over five years designed to establish India as a global biopharma manufacturing hub. This isn't just about infrastructure, it's about addressing India's rising burden of non-communicable diseases like diabetes, cancer, and autoimmune disorders while positioning Indian manufacturers as reliable global suppliers of biologics and biosimilars. The government is backing this vision with substantial talent development. Three new National Institutes of Pharmaceutical Education and Research (NIPERs) will be established alongside upgrades to seven existing ones, while a network of 1,000 accredited clinical trial site...